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Abstract
Hypoxia-inducible factor 1 (HIF-1), a heterodimeric transcription factor that mediates the adaptation of tumor cells and
tissues to the hypoxic microenvironment, has attracted considerable interest as a potential therapeutic target. Tirapazamine
(TPZ), a well-characterized bioreductive anticancer agent, is currently in Phase II and III clinical trials. A major aspect of the
anticancer activity of TPZ is its identity as a tumor-specific topoisomerase IIa inhibitor. In the study, for the first time, we
found that TPZ acts in a novel manner to inhibit HIF-1a accumulation driven by hypoxia or growth factors in human cancer
cells and in HepG2 cell-derived tumors in athymic nude mice. We investigated the mechanism of TPZ on HIF-1a in HeLa
human cervical cancer cells by western blot analysis, reverse transcription-PCR assay, luciferase reporter assay and small
interfering RNA (siRNA) assay. Mechanistic studies demonstrated that neither HIF-1a mRNA levels nor HIF-1a protein
degradation are affected by TPZ. However, TPZ was found to be involved in HIF-1a translational regulation. Further studies
revealed that the inhibitory effect of TPZ on HIF-1a protein synthesis is dependent on the phosphorylation of translation
initiation factor 2a (eIF2a) rather than the mTOR complex 1/eukaryotic initiation factor 4E-binding protein-1 (mTORC1/4E-
BP1) pathway. Immunofluorescence analysis of tumor sections provide the in vivo evidences to support our hypothesis.
Additionally, siRNA specifically targeting topoisomerase IIa did not reverse the ability of TPZ to inhibit HIF-1a expression,
suggesting that the HIF-1a inhibitory activity of TPZ is independent of its topoisomerase IIa inhibition. In conclusion, our
findings suggest that TPZ is a potent regulator of HIF-1a and provide new insight into the potential molecular mechanism
whereby TPZ serves to reduce HIF-1a expression.
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Introduction
Hypoxia is a common phenomenon occurring in the majority of
human tumors [1]. The microenvironment of tumors is unlike that
of normal tissues because the proliferative status of the tumor cells
and an irregular vascular supply result in the development of
hypoxia [2,3]. The presence of hypoxia is significantly associated
with aggressive tumor progression, resistance to chemotherapy and
radiation,and poor prognosis [4]. Tumor cellsand tissues adapt to a
hypoxic microenvironment through the activation of a number of
hypoxia-related molecules and pathways, among which hypoxia-
inducible factor 1 (HIF-1) is the most predominant one [5].
HIF-1 is overexpressed in common cancers and contributes to
tumor growth and angiogenesis [6]. HIF-1 is a heterodimeric
protein that is composed of two subunits: the O2-regulated HIF-1a
subunit and the constitutively expressed HIF-1b subunit [7]. In
normoxia, the hydroxylation of two proline residues and the
acetylation of a lysine residue at its oxygen-dependent degradation
domain (ODDD) promote the interaction of HIF-1a with the von
Hippel-Lindau (pVHL) ubiquitin E3 ligase complex and thus
marks HIF-1a for degradation by the ubiquitin-proteasome system
[8]. However, under hypoxic conditions, the low availability of
oxygen results in the inhibition of prolyl hydroxylase activity and,
consequently, in the increase of HIF-1a stability [4]. Although the
oxygen-dependent regulation of degradation is the primary
mechanism of HIF-1a accumulation, HIF-1a is also known to
be regulated at the translational level [4,6]. Recent studies have
shown that two distinct pathways regulate HIF-1a protein
synthesis. One is the phosphorylation of eIF2a, which is
responsible for a rapid inhibition of translation initiation, and
the other is a reduction in the phosphorylation of 4E-BP1, a
protein that is regulated by mTORC1 [9,10].
Due to the importance of HIF-1a in cancer, targeting HIF-1a
could become a novel approach in cancer therapy. It has been
reported that HIF-1a-deficient cells are more susceptible to
chemotherapeutic agents and radiotherapy [11]. Tirapazamine
(TPZ) represents a class of hypoxia-selective cytotoxins and is
currently in phase II and III clinical trials for the treatment of head
and neck cancers and cervical cancer. TPZ also functions as a
hypoxia-activated topoisomerase IIa poison[12]. Previous studies
have shown that a number of DNA damage-inducing agents can
inhibit HIF-1a protein accumulation [4,13]. Based on these
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13910studies, we investigated whether TPZ could affect the activity of
HIF-1a. Interestingly, our previous results revealed that TPZ
induced a remarkable reduction in HIF-1a protein levels. In this
study, we used human cervical-cancer (HeLa) cells to characterize
and investigate the mechanisms involved in the reduction of HIF-
1a protein levels by TPZ. The present study not only provides a
better understanding of the HIF-1a signaling pathway, but also
identifies the regulation of HIF-1a protein synthesis as an
important target of HIF-1a-inhibitory compounds.
Results
TPZ inhibits the cellular accumulation of HIF-1a protein
To investigate whether TPZ affects cellular HIF-1a protein
expression, we used various concentrations of TPZ to treat HeLa
cells under hypoxic conditions. As expected, hypoxia induced a
robust accumulation of HIF-1a protein, and the addition of TPZ
decreased hypoxia-induced HIF-1a protein expression in a
concentration-dependent manner (Fig. 1A). Similarly, TPZ also
blocked the accumulation of HIF-1a protein induced by the growth
factors insulin and EGF (Fig. S1A), both of which are known to
stimulate HIF-1a expression through the PI3K/Akt signaling
pathway [14,15]. Given that the inhibition of HIF-1a accumulation
in hypoxic cells might be correlated with TPZ-induced cytotoxicity,
parallel studies of cell viability were performed (Fig. S1B). After the
HeLa cells were treated with TPZ (20 mM) for 4 h under hypoxic
conditions, no significant alteration of cell viability was observed
relative to the untreated control group. Next, in order to address
whether the inhibition of HIF-1a by TPZ was cell line specific, we
extended these studies to a diverse set of tumor cell lines with tissues
of various origins, including the hepatic-cancer cell lines HepG2 and
SMMC-7721, the colon-cancer cell line HCT116, the breast-cancer
Figure 1. TPZ decreases hypoxia-induced HIF-1a protein accumulation. HeLa cells (A), and HEK-293, OVCAR8, HepG2, SMMC-7721 and
HCT116 cells (B) were exposed to hypoxia and a gradient of concentrations of TPZ for 4 h. HIF-1a and b-actin protein levels were detected by
western-blot analysis of whole-cell extracts, as described in the Materials and Methods. (C) Effect of TPZ treatment on the expression level of HIF-1a in
HepG2 cell-derived tumors, as determined by immunoblot analysis. (D) Densitometry analyses of (C). (E) Hypoxia-dependent HIF-1a transcriptional
activity was measured using HRE-dependent reporter assays, as described in the Materials and Methods. HeLa cells were transiently transfected with
the HRE-Luc plasmid and then treated with TPZ for 8 h under hypoxic conditions. Luminescence was measured and fold stimulation was obtained by
normalizing the relative luciferase activity to that of untreated cells under hypoxic conditions.
doi:10.1371/journal.pone.0013910.g001
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Fig. 1B shows that, under hypoxic conditions, HIF-1a accumulation
is suppressed by TPZ in all cell lines. Although cell-based
experiments demonstrated the suppression of HIF-1a by TPZ in
vitro,t h ein vivo HIF-1a-inhibitory activity of TPZ remained to be
elucidated. Accordingly, we evaluated the effect of TPZ administra-
tion on the expression level of HIF-1a protein inHepG2 cell-derived
tumors in athymic nude mice. TPZ administration was found to
diminish the level of HIF-1a in the tumors (Fig. 1C and D).
Consistent with the inhibition of HIF-1a accumulation, TPZ also
mediated the concentration-dependent inhibition of HIF-1-mediat-
ed transcriptional activity under hypoxic conditions, as determined
using a hypoxia-responsive reporter construct (Fig. 1E). The
employed construct contains a luciferase gene under the control of
the hypoxia response elements (HREs). These results collectively
indicate that TPZ treatment decreases the expression of HIF-1a in
vitro and invivo and thatTPZ demonstratesthisactivityacrossvarious
human tumor cell lines and under stimulation with growth factors.
TPZ does not affect HIF-1a mRNA expression or protein
degradation, but decreases HIF-1a protein synthesis
To ascertain whether the reduction of HIF-1a by TPZ occurs at
the transcriptional level, we used reverse transcription polymerase
chain reaction (RT-PCR) to study the effect of TPZ on the
accumulation of HIF-1a mRNA. RT-PCR analysis indicated that
HIF-1a mRNA levels were not significantly changed after TPZ
treatment in HeLa cells (Fig. 2A and S2A). Furthermore, the similar
results were also observed in other two cell lines (HCT116 and
A549) (Fig. S2B and C). Following this observation, we investigated
the effect of TPZ on HIF-1a posttranscriptional regulation.
Cycloheximide (CHX) was used to prevent de novo protein synthesis;
thus, HIF-1a levels would primarily reflect the protein degradation
process. We exposed HeLa cells to CHX under hypoxic conditions
in the presence or absence of TPZ at different time points and
estimated the expression levels of HIF-1a. As shown in Fig. 2B,
although the intensity of the HIF-1a signal was somewhat reduced
inTPZ-treatedcells,thedegradationratesofHIF-1aweresimilarin
treated and untreated cells. The level of HIF-1a protein in cells
results from a balance between protein synthesis (translation) and its
degradation [16]. To test the possibility that TPZ-mediated
inhibition of HIF-1a accumulation is due to reduced HIF-1a
protein synthesis, HeLa cells were pretreated with MG132 (a
specific proteasome inhibitor) before the addition of TPZ and the
induction of hypoxic challenge to prevent ubiquitin-dependent
HIF-1a degradation. As expected, we detected a pronounced
accumulation of HIF-1a protein at higher molecular weights,
indicatingthatpolyubiquitinatedHIF-1aproteinspeciesforminthe
presence of MG132 (Fig. 2C). However, MG132 treatment did not
reverse the TPZ-triggered decrease of HIF-1a protein levels
(Fig. 2C). In addition to the ubiquitin-proteasome system (a non-
lysosomal pathway), the lysosomal pathway is also responsible for
protein degradation in cells [17,18]. To further rule out the
possibility that the lysosomal pathway participates in the inhibition
of HIF-1a by TPZ, we utilized chloroquine (CQ), a lysosome
inhibitor, to block nonspecific HIF-1a degradation. In keeping with
the results obtained with MG132, the inhibition of protein
degradation by CQ did not abolish the inhibitory effect of TPZ
on HIF-1a protein levels (Fig. 2D and Fig. S2B). The findings
described above indicate that TPZ interferes with the protein
synthesis process and does not accelerate HIF-1a proteasome- or
lysosome-mediated degradation. Together with the results of the
protein degradation-rate experiments, our data also suggest that the
reduction of HIF-1a protein levels by TPZ is due to the reduced
synthesis of HIF-1a rather than the enhanced degradation of the
protein. To more directly assess the effects of TPZ on the rate of de
novo synthesis of the HIF-1a protein, cells were pretreated with
CHX for three hours under normoxia to inhibit new protein
synthesis and then incubated in fresh medium. These CHX-
pretreated cells were exposed to hypoxic conditions, with or without
TPZ, for different periods, and HIF-1a protein levels were analyzed
by western blotting. As shown in Fig. 2E and Fig. S2C, significantly
more HIF-1a protein accumulated in untreated cells than in treated
cells at all times tested. This result further confirmed that TPZ
decreases the rate of HIF-1a protein synthesis.
TPZ inhibits the activation of the mTORC1/4E-BP1
pathway, which had negligible effect on the TPZ-
triggered reduction of HIF-1a
HIF-1a protein synthesis is regulated by mTORC1 signaling,
which phosphorylates the key protein-synthesis regulator 4E-BP1;
thus, the levels of phosphorylated 4E-BP1 can be used as an
indicator of mTORC1 activity [19]. The phosphorylation of 4E-
BP1 results in an abrogated interaction with eIF4E and thus
stimulates cap-dependent translation [9]. To examine the potential
involvement of this pathway in TPZ-driven events, we measured
the phosphorylation status of three key proteins: mTOR, 4E-BP1
and Akt. Treatment with TPZ resulted in decreased phosphory-
lation of mTOR and 4E-BP1 as well as the reduction of HIF-1a
accumulation (Fig. 3A), indicating an inhibition of mTORC1
signaling. The results of an in vitro kinase assay further confirmed
that mTORC1 kinase activity was suppressed (Fig. 3B). Notably,
TPZ also caused an apparent increase in Akt phosphorylation at
Ser473 but induced no significant alteration in Akt phosphoryla-
tion at Thr308 (Fig. 3A). This result is in agreement with recent
reports describing the activation of Akt at Ser473 as the result of
mTORC1 inhibition [20,21]. Earlier studies have shown that the
TSC1-TSC2 tumor suppressor complex is a key negative regulator
of mTORC1 [22]. To directly address the contribution of the
mTORC1/4EBP1 pathway to the downregulation of HIF-1a by
TPZ, we knocked down TSC2 and 4EBP1 expression using
specific siRNAs. Although both of the siRNAs completely silenced
the expression of their target genes, neither of them abolished the
effect of TPZ on HIF-1a levels (Fig. 3D and 3E). Our results
provide evidence that the suppression of mTORC1/4EBP1
signaling was not important for the TPZ-triggered reduction of
HIF-1a protein levels. Additionally, we also found that TPZ did
not affect a series of signaling pathways correlated with mTORC1
signaling, such as the Erk, AMPK, Hsp90 and Hsp70 pathways
(Fig. S3).
A direct role for eIF2a phosphorylation in HIF-1a
downregulation by TPZ
In addition to the mTORC1 pathway, another major pathway
through which protein synthesis is controlled is the eIF2a pathway.
Various cellular stress signals can induce the phosphorylation of
eIF2a at Ser51 and mediate the global inhibition of protein
synthesis [23,24]. We therefore monitored the accumulation of
phosphorylated eIF2a and its downstream products. TPZ induced
robust eIF2a phosphorylation (Fig. 4A) and enhanced its
downstream effects, including the upregulation of transcription
factor 4 (ATF4) and ATF4’s transcriptional target GADD153
(Fig. 4B). Furthermore, HeLa cells transiently transfected with a
luciferase gene under the control of ODD were utilized to evaluate
the effect of TPZ treatment on basal protein synthesis.
Importantly, the ODD region of HIF-1a is sufficient for oxygen-
dependent degradation [25]. As shown in Fig. 4C, TPZ exposure
produced a general translational arrest of protein synthesis. In
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eIF2a is required for the TPZ-dependent inhibition of HIF-1a
protein synthesis by transfecting cells with siRNA targeting eIF2a.
The knockdown of eIF2a attenuated basal HIF-1a protein levels
and partially reversed the effects of TPZ on HIF-1a translation
repression (Fig. 4D). Thus, TPZ induced down-regulation of
HIF-1a is largely eIF2a phosphorylation dependent.
TPZ reduces HIF-1a protein levels only under hypoxic
conditions, and this activity is independent of TPZ’s
inhibition of topoisomerase II
TPZ, a bioreductive drug, is selectively toxic to hypoxic cells [26].
In order to examine whether the effect of TPZ on the expression of
HIF-1aisdependent on oxygenconcentrations,wetested the effect of
TPZonHIF-1aexpressionunder aerobic conditions. The additionof
Figure 2. TPZ does not affect HIF-1a mRNA expression or protein degradation, but decreases HIF-1a protein synthesis. (A) HeLa cells
were exposed to varying concentrations of TPZfor 4 h or a single concentration for the indicated times. Then, the total RNA was extracted andanalyzed
forHIF-1amRNAexpression byRT-PCR, usingGAPDHasacontrolgene.(B) Cellsexposedtohypoxiaovernightweretreatedwithcycloheximide(CHX)in
the presence or absence of 20 mM TPZ for various periods, and HIF-1a protein levels were measured by western-blot analysis. HeLa cells were treated
with TPZ, together with MG132 (C) or chloroquine diphosphate (CQ) (D), under the indicated conditions, followed by immunoblotting with anti-HIF-1a
or anti-b-actin antibodies. Cells were pretreated for 30 min with MG132 and CQ to allow functional inhibition of the proteasome and lysosome. (E) HeLa
cells were pre-incubated with CHX for 3 h in normoxic conditions and then placed in fresh medium and treated with or without 20 mM TPZ for the
indicated times under hypoxic conditions. The cells were harvested and lysates were immunoblotted with an anti-HIF-1a antibody.
doi:10.1371/journal.pone.0013910.g002
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1a in aerobic HeLa cells (Fig. 5A). HIF-1a accumulation induced by
the prolyl hydroxylase inhibitor cobalt chloride (CoCl2), a well-
characterized hypoxia mimetic agent [3], was unaffected by
normoxia and treatment with TPZ (Fig. 5B). All of these findings
collectively indicate that TPZ decreases the cellular accumulation of
HIF-1a protein only under hypoxic conditions (Fig. 5C).
Additionally, TPZ has been demonstrated to be a hypoxia-
activated topoisomerase II poison [12]. Here, in an attempt to
explore whether topoisomerase II inhibition is required for the
reduction of HIF-1a protein levels by TPZ, we employed two
potent topoisomerase II inhibitors: etoposide and adriamycin [27].
As shown in Fig. 5D, only TPZ treatment resulted in the
downregulation of HIF-1a protein levels, while etoposide and
adriamycin had no effect on the expression of HIF-1a. Thus, there
is no direct correlation between topoisomerase II inhibition and
HIF-1a reduction. Furthermore, we tested the HIF-1a protein
levels, with or without treatment with TPZ, in HeLa cells that
were either untransfected or transfected with siRNA targeting
topoisomerase IIa (Fig. 5E). Topoisomerase IIa-targeting siRNA
completely silenced the expression of topoisomerase IIa and
disrupted phosphorylated Chk2 (a critical mediator of topoisom-
erase II-induced DNA damage) [28], indicating that topoisomer-
ase IIa was inactive in these cells. The transfection of
Figure 3. Effects of TPZ on Akt and the mTORC1 pathway in HeLa cells. (A) Cells were cultured in hypoxia for 4 h in the presence of the
indicated concentrations of TPZ before western-blotting analysis. (B) Immunoprecipitates prepared from the lysates of HeLa cells with Raptor
antibody were used in kinase assays with full-length 4EBP1 as the substrate. (C) Immunoblotting was used to detect the phosphorylation of Akt at
Ser473 or Thr308 after TPZ treatment. HeLa cells were transfected with siRNAs specifically targeting TSC2 (D) and 4E-BP1 (E) or control siRNAs, as
described in the Materials and Methods. Transfected cells were incubated with or without 20 mM TPZ for 4 h under hypoxic conditions. Proteins were
detected by western-blot analysis using specific antibodies.
doi:10.1371/journal.pone.0013910.g003
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any detectable effects on the TPZ-mediated reduction in HIF-1a
protein accumulation (compare lane 2 with lane 6). These findings
suggest that the TPZ-induced reduction in HIF-1a expression is a
topoisomerase II-independent phenomenon.
In vivo efficacy of TPZ in an athymic nude mouse model
Because our previous results revealed that TPZ modulate HIF-
1a protein synthesis by phosphorylation of eIF2a in vitro, we next
determined whether these results could be translated into an in vivo
xenograft model. A short times (9 days) TPZ administration was
observed to decrease the expression level of HIF-1a protein
(Fig. 1C and D). This study was confirmed by performing
immunofluorescence of HIF-1a and p-eIF2a proteins in tumor
sections of both groups of animals. TPZ caused a reduction in
HIF-1a-positive staining but induced an apparent increase in p-
eIF2a-positive staining in tumor tissues of animals (Fig. 6A and B),
which were consistent with our in vitro studies.
Considering several articles have been reported that HIF-1a
plays an active role in tumor progression and transplantation of
tumors lacking HIF into immunodeficient mice results in
decreased tumor growth [11,29], we next asked whether the
observed effect of TPZ has any impact on tumor physiology. As
expected, the administration of TPZ (30 mg/kg every 2 days)
inhibited the tumor growth, with T/C value 51.5% and inhibition
rate 36.5%. The relative tumor volume (RTV) of TPZ-treated
group was remarkably decreased from that of vehicle group
(p,0.007) (Fig. 6D). Collectively, these data further suggest that
TPZ has the potential to inhibit the tumorigenicity of HepG2 cells
in vivo.
Figure 4. A direct role of eIF2a phosphorylation in HIF-1a downregulation by TPZ. (A) HeLa cells treated with indicated concentrations of
TPZ for 4 h under hypoxic conditions. Total lysates were probed for expression of HIF-1a, p-eIF2a, and eIF2a, while b-actin served as a loading
control. (B) HeLa cells were exposed to varying concentrations of TPZ for 4 h. GADD153 mRNA levels were determined by real-time PCR. The relative
fold change of GADD153 mRNA compared to GAPDH mRNA in untreated cells under hypoxia was arbitrarily set as 1.0. (C) The effect of TPZ treatment
to basal protein synthesis was measured using ODD-dependent reporter assays. HeLa cells were transiently transfected with the ODD-Luc plasmid
and then treated with TPZ for 4 h under normoxia or hypoxia. Luminescence was measured and fold stimulation was obtained by normalizing the
relative luciferase activity of cells cultured under hypoxic conditions to those of untreated cells cultured under normoxic conditions. (D) Cells were
untransfected or transfected with eIF2a-targeting siRNA for two days, followed by treatment with or without 20 mM TPZ. Western blotting of cell
lysates was performed using the indicated antibodies.
doi:10.1371/journal.pone.0013910.g004
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HIF-1 is constitutively upregulated in various types of cancer
and plays a major role in tumor progression [11]. In addition to
serving as a surrogate marker of tumor responsiveness to therapy,
HIF-1 has rapidly attracted interest both for its potential role as a
therapeutic target and its involvement in fundamental physiolog-
ical and pathophysiological processes, including angiogenesis,
resistance to chemotherapy and radiotherapy, tumor invasiveness
and poor prognosis of cancer patients [5,29,30]. Due to the
potential role of HIF-1 as a target for cancer therapy, the
development of small-molecule HIF-1 inhibitors represents a
major challenge in the field of cancer treatment. This study is the
first to demonstrate that TPZ, a hypoxia-selective cytotoxin,
induces an unexpected downregulation of hypoxia-dependent and
mitogen-dependent HIF-1a accumulation in human tumor cell
Figure 5. TPZ reduces HIF-1a protein only under hypoxic conditions, and its activity is independent of its topoisomerase II
inhibition. (A) HeLa cells were exposed to normoxic conditions for 4 h in the presence of TPZ. (B) Cells were treated with varying concentrations of
TPZ for 4 h, as indicated, in the presence of the hypoxia-mimetic agent cobalt chloride (CoCl2). (C) HeLa cells were treated for 4 h in normoxia,
hypoxia or with CoCl2 in the presence of TPZ at the indicated concentrations. (D) Cells were treated with 20 mM TPZ, 20 mM etoposide and 10 mM
adriamycin for 4 h. (E) Topoisomerase IIa was knocked down using siRNA, as described in the Materials and Methods, followed by drug treatment
(20 mM TPZ, 20 mM etoposide and 10 mM adriamycin). Proteins were detected by western-blot analysis.
doi:10.1371/journal.pone.0013910.g005
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toxicity of TPZ within a relatively short treatment time (4 h), thus,
the observed inhibition of HIF-1a accumulation by TPZ is not
attributable to cell death.
The accumulation of HIF-1a is regulated through both protein
degradation and protein synthesis. In the present study, we found
that TPZ inhibits HIF-1a accumulation without affecting HIF-1a
protein degradation and mRNA levels. These observations
support the hypothesis that the TPZ-dependent reduction of
HIF-1a accumulation is due to the decrease of de novo HIF-1a
protein synthesis.
HIF-1a protein translation has emerged as an important
regulatory mechanism of HIF-1a-inhibitory compounds. HIF-1a
protein translation is known to be regulated through the
mTORC1 [22]pathway. The mTORC1 pathway regulates
translation with such downstream effectors as 4E-BP1 and
ribosomal protein S6 kinase (p70S6K) [22]. Hypophosphorylated
4E-BP binds eIF4E, thereby preventing its association with eIF4G
and inhibiting cap-dependent translation [9]. In the present study,
TPZ was found to inhibit the phosphorylation of mTOR and 4E-
BP1, which accompanied the loss of HIF-1a expression.
Therefore, given the key role of this pathway in the regulation
of HIF-1a translation, our results strongly suggest that TPZ-
induced suppression of the mTORC1 pathway might serve to
inhibit HIF-1a protein translation. However, the near-complete
abrogation of TSC2 and 4E-BP1 expression through siRNA-
mediated knockdown did not abolish the effect of TPZ on HIF-1a
levels. These results indicate that the suppression of mTORC1/
4E-BP1 signaling had a negligible effect on the TPZ-triggered
reduction of HIF-1a. Currently, a number of compounds with
different anticancer molecular targets, such as YC-1 [29] and 2-
methoxyestradiol [31], have been reported to reduce hypoxia-
induced HIF-1a accumulation through a translation-dependent
mechanism. Most of these compounds were demonstrated to
Figure 6. The effect of TPZ on HepG2 human xenograft models. The mice transplanted with HepG2 human xenograft were randomly divided
into two groups and given injection of TPZ (30 mg/kg) or vehicle every 2 days. Representative photomicrographs (magnification, x100) showing
immunofluorescence staining for HIF-1a (A) and p-eIF2a (B) in tumor sections of vehicle–treated and TPZ-treated mice. The immunostaining data
were confirmed in two or more specimens of each group. (C) Tumor volume are expressed as mean 6 SD. (D) Relative tumor volume are expressed as
mean 6 SD. (**p,0.01, relative to vehicle group).
doi:10.1371/journal.pone.0013910.g006
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siRNA nor the transfection of dominant-negative mutants was
used to further confirm that the reduction of HIF-1a was due to
interference with the mTORC1/4E-BP1 pathway. Notably,
Garcia-Maceira et al. [6] reported that silibinin was more effective
in inhibiting HIF-1a accumulation than rapamycin, which
suggests the participation of an additional mechanism in addition
to repression of the mTORC1/4E-BP1 pathway. Accordingly, it is
reasonable to believe that the reduction of HIF-1a is not linked to
the repression of mTORC1 signaling. Therefore, further studies
are needed to explore additional mechanisms that are related to
protein synthesis in addition to mTORC1/4E-BP1 inactivation.
A recent study reported that the phosphorylation of eIF2a
might play a role in HIF-1a translational regulation. Normally,
during protein synthesis, the exchange of eIF2a-GDP to eIF2a-
GTP is required for the re-formation of ternary translation
initiation complexes [32,33]. For eIF2a-GDP to be recycled,
eIF2B is required. Phosphorylated eIF2a at serine 51 binds to
eIF2B with high affinity. Thus, eIF2B cannot recycle eIF2a-GDP,
thereby leading to global protein translation arrest. Decreased
initiation, paradoxically, leads to the increased expression of ATF4
[34]. We have shown that treatment with TPZ upregulates the
phosphorylation of eIF2a and its downstream effector ATF4,
which parallels the reduction of HIF-1a protein accumulation.
ATF4 induces the expression of numerous genes, such as
GADD153 and VEGF [33]. VEGF is considered a classic HIF-1
target gene. Measuring the mRNA expression of VEGF by PCR,
we found that it is not affected by TPZ treatment, while the
mRNA level of PHD3 (a HIF-1 target gene) is reduced and the
GADD153 mRNA level is enhanced (Fig. 4B and S4). PCR results
further suggested the potential connection between TPZ-triggered
eIF2a phosphorylation and HIF-1a inhibition. Indeed, the
knockdown of eIF2a attenuated basal HIF-1a protein levels and
partially reversed the effects of TPZ on HIF-1a translational
repression. Furthermore, immunofluorescence analysis revealed
that the down-regulation of HIF-1a was observed to be
concomitant with increased eIF2a phosphorylation in TPZ-
treated cell-originated tumors. In conclusion, these data indicate
that TPZ induces the phosphorylation of eIF2a and that this effect
likely accounts for its HIF-1a inhibitory activity.
Of note, stress to the endoplasmic reticulum (ER) activates a set
of signaling pathways collectively termed the unfolded protein
response (UPR) [24,34]. One branch of the UPR is initiated by
activation of the ER-stress sensor PERK, an eIF2a kinase [35].
Therefore, we sought to examine whether TPZ was able to cause
ER stress. Unexpectedly, unlike tunicamycin (Tm, an agent that
can induce ER stress), TPZ did not upregulate the canonical UPR
indicator Grp78 and induce the appearance of spliced Xbp1
mRNA (Fig. S5), indicating that TPZ selectively engages in the
translational-control branch of the UPR by inducing eIF2a
phosphorylation without causing ER stress or activating the
transcription-dependent branch of the UPR.
Certain topoisomerase II inhibitors have been found to inhibit
HIF-1 activity, such as NSC644221 [16] and adriamycin [13,36].
Particularly, NSC644221is known to inhibit HIF-1a protein
expression in a cell type-specific and topoisomerase II-dependent
manner. This potential correlation between HIF-1a and topoisom-
erase II attracted our interest. We observed that etoposide and
adriamycin had no effect on the expression of HIF-1a, which is
consistent with recent studies [13,36]. Additionally, the silencing of
topoisomerase IIa did not abolish the TPZ-mediated reduction of
HIF-1a protein accumulation. Unexpectedly, our studies revealed a
lack of direct correlation between topoisomerase II inhibition and
HIF-1a reduction, and TPZ-driven HIF-1a reduction was not a
consequence of TPZ-mediated topoisomerase II inhibition, sug-
gesting that TPZ targets both HIF-1a and topoisomerase II.
Moreover, in topoisomerase IIa knockdown cells, TPZ was able to
decrease HIF-1a expression, which was consistent with the change
in phosphorylation of eIF2a and with mTORC1/4E-BP1 inhibi-
tion. However, etoposide and adriamycin treatments, concurrently
performed, had no effect on the expression of HIF-1a regardless of
mTORC1/4E-BP1 inhibition (Fig. 5E). Similar results were
observed in cells untransfected with siRNA (Fig. 5D). These
findings further suggest that the inhibitory effect of TPZ on HIF-1a
protein is dependent on the phosphorylation of eIF2a rather than
the mTORC1/4E-BP1 pathway.
Transplantation of tumors lacking HIF into athymic mice
resulted in increased responsiveness to the treatment with
carboplatin, etoposide and ionizing radiation, all of which induce
DNA damage, primarily by double-strand breaks. Recent findings
provided evidence that double-strand break repair enzymes
(potential targets of HIF-1) are associated with responsiveness to
tumor therapy [11]. In this study, we found that TPZ acts in a
novel manner to inhibit HIF-1 activity by stimulating the
phosphorylation of eIF2a but not mTORC1/4E-BP1 repression.
The new mode of action exhibited by TPZ may, in part, explain
why the combination of TPZ with conventional anticancer
treatments (IR, VP-16, cisplatin, etc.) is particularly effective
[37,38,39]. The present study not only provides a new
understanding of the HIF-1a-inhibitory activity and the underly-
ing mechanisms of TPZ, but also underscores its potential for
further research and development as an HIF-1a inhibitor, alone or
in combination with other agents, to produce even stronger
anticancer activities.
Materials and Methods
Ethics Statement
This study was carried out in accordance with the National
Institute of Health Guide for the Care and Use of Laboratory
Animals. The protocol was approved by the Committee on the
Ethics of Animal Experiments of the Zhejiang University (Permit
Number: Zju2009101003 and Zju2010101032).
Reagents and antibodies
TPZ was supplied by Topharman Shanghai Co., Ltd. The
compound was dissolved in dimethylsulfoxide (DMSO) (40.0 mM
stock solution) and stored at 220uC. The stock solution was freshly
diluted with medium before use. The final DMSO concentration
did not exceed 0.1% (v/v). MG132, cycloheximide (CHX), cobalt
chloride (CoCl2), chloroquine diphosphate salt (CQ), etoposide
and adriamycin were obtained from Sigma-Aldrich (St. Louis,
MO, USA). Epidermal growth factor (EGF) was purchased from
Invitrogen (Carlsbad, CA, USA). Insulin was purchased from
Sigma–Aldrich. The primary antibody for HIF-1a was purchased
from the BD Transduction Laboratories (San Jose, CA, USA). The
primary antibodies for p-Akt (Ser473), p-Akt (Thr308), Akt, p-4E-
BP1 (Ser65), eIF2a, p-eIF2a (Ser51), CREB-2 (ATF4), topoisom-
erase IIa, TSC2, Raptor, b-actin, Hsp90, Hsp70 and p-Erk were
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The
primary antibody for 4E-BP1, LC3B, p-AMPK(Thr172), mTOR
and p-mTOR (Ser2448) were obtained from Cell Signaling
Technology (Beverly, MA, USA). The primary antibody for p-
chk2 (T68) was from R&D Technology. Secondary antibodies for
rabbit IgG, goat IgG and mouse IgG were from Santa Cruz
Biotechnology. Enhanced chemiluminescence, a western blot
detection reagent, was obtained from Pierce Chemical (Rockford,
IL, USA).
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Human hepatic-cancer HepG2 and SMMC-7721 cells, cervi-
cal-cancer HeLa cells, colon-cancer HCT116 cells, breast-cancer
OVCAR8 cells and embryonic-kidney HEK-293 cells were
obtained from the Cell Bank of the China Science Academy
(Shanghai, China). Cells were normally cultured with the Cell
Bank-required medium at 37uC in a humidified atmosphere with
5% CO2. All media were supplemented with heat-inactivated fetal
bovine serum (FBS) (Gibco BRL, Grand Island, NY) plus penicillin
(100 units/ml) and streptomycin (100 mg/ml). Moderately hypoxic
conditions (0.6% O2) were achieved by putting cells in a hypoxia
incubator (Forma Scientific, Inc., Marietta, OH) filled with a
mixture of 0.6% O2,5 %C O 2 and 94.4% N2.
Western blotting
Exponentially growing cells (70–80% confluence) in complete
medium were treated with different concentrations of TPZ and/or
other agents for the indicated times under normoxic or hypoxic
conditions. The cells were collected and lysed in 2X SDS gel-
loading buffer [24 mM Tris-HCl (pH 6.8), 0.02% mercaptoeth-
anol, 4% SDS, 0.4% bromphenol blue, 20% glycerol] and then
boiled for 10–15 minutes. Equal volumes of cell lysates were
resolved on 8%–15% SDS-PAGE gels, and the proteins were
transferred to PVDF membranes (Pierce Chemical). The blots
were incubated with the indicated primary antibodies and then the
appropriate horseradish peroxidase-conjugated secondary anti-
bodies. The signals were visualized by the ECL Plus western-
blotting detection system (Pierce Chemical).
Reverse transcription-PCR
Total RNA from HeLa cells was isolated using the Trizol reagent
(Sangon BiotechCo., Ltd), and cDNA was synthesized using2 mgo f
total RNA with random hexamer primers and the Moloney murine
leukemia virus reverse transcriptase (M-MuLV RT) (Fermentas
International Inc., Burlington, Ontario, Canada). The conditions
used for reverse transcription-PCR were as follows: 10 min at 25uC,
60 min at 42uC and 15 min at 72uC. The cDNA was subjected to
PCR amplification using the following forward and reverse primer
sets: HIF-1a, forward primer: 59-TCACCACAGGACAG TA-
CAGGATGC-39 and reverse primer: 59-CCAGCAAAGTTAAA-
GCATCAGG TTCC-39; VEGF, forward primer: 59-AGGAGGG-
CAGAATCATCACG-39 and reverse primer: 59-CAAGGCCCA-
CAGGGATTTTCT-39; Xbp1, forward primer: 59-CCTTG
TAGTTGAGAACCAGG-39 and reverse primer: 59-GGGGC-
TTGGTATATATGTG G-39; GRP78, forward primer: 59-GTA-
TTGAAA CTGTAGGAGGTGTC-39 and reverse primer: 59-
TATTACAGCACTAGCAGATCAG-39; GADD153, forward
primer: 59- GCACCTCCCAGAGCCCTCACTCTCC-39 and
reverse primer: 59-GTCTACTC CAAGCCTTCCCCCTGCG-
39; PHD3, forward primer: 59-TCAAC TTCCTCCTGTC CCT-
CATC-39 and reverse primer: 59-GCGAACATAACCTGTCC-
CATTTC-39; GAPDH, forward primer: 59-GTCATCCATGA-
CAACTTTGG-39 and reverse primer: 59-GAGCTTGA CAAA-
GTGGTCGT-39. The housekeeping gene GAPDH wasused as the
internal standard. PCR products were separated on 1.0% agarose
gel and visualized by ethidium bromide staining. Gels were
photographed using a Gel DOC 2000 image analyzer (Bio-Rad,
Hercules, CA, USA). The quantitative real-time RT-PCR analysis
was performed by TAKARA SYBR Premix EXTaqTM. The
reaction mixtures containing SYBR Green were composed
following the manufacturer’s protocol. The cycling program was
95uC for 30 s, 58uCo r7 0 uC (GADD153) for 20 s, and 72uC for
30 s followed by 40 cycles using an Eppendorf epGradient
Mastercycler (Eppendorf, Hamburg, Germany).
Small interfering RNA (siRNA) transfection
siRNA duplexes against human 4E-BP1, TSC2, topoisomerase
IIa, eIF2a and control scrambled siRNA were synthesized by
Shanghai GenePharma Co., Ltd. The sense strands of siRNAs
against 4E-BP1, TSC2, topoisomerase IIa, and eIF2a were as
follows: 4E-BP1: GGUACCAGG AUCAUCUAUGTT [40]; TS-
C2: CAAUGAGUCACAGUCCUUU GA (a) and AAAGU UCA-
CCUACUGCUGGCA (b) [41]; topoisomerase IIa: GGUAUUC-
CUGUUGUUGAAC [42]; eIF2a: GGCUUGUUAUGGUUAU-
GAA(a), CCUCGGUAUGUAAUGACUA(b) and GAGAGG-
CUUGAAAGAGAAA(c) [43]. Briefly, HeLa cells were seeded
into six-well plates and grown to 30–40% confluence before
transfection.Cellsweretransfected with double-strandedsiRNAs(at
final concentrations of 80–100 nM) for 4–6 h by the oligofectamine
method, according to the manufacturer’s protocol (Invitrogen), and
incubatedinfreshmediacontaining10%FBSfortheindicated time
before starting an experiment.
Luciferase reporter assays
HeLa cells were seeded into 96-well plates and grown to 80%
confluence before transfection. Cells were cotransfected with renilla
luciferase (internal control for transfection efficiency) and plasmids
HRE-luciferase-pGL3 or ODD-luciferase-pcDNA3 (Addgene, Inc.)
encoding a firefly luciferase reporter driven by a promoter
containing an HRE or ODD, respectively, using Lipofectamine
2000 reagent (Invitrogen) according to the manufacturer’s instruc-
tions. Luciferase activity was measured using the Dual-Luciferase
reporter assay system (Promega, Madison, Wis., USA). In the assay,
firefly luciferase activity was normalized by renilla luciferase.
Transient transfection assays
HeLa cells were seeded into 6-well plates in standard growth
medium. After an overnight culture, the cells were transiently
transfected with 4 mg Xbp1-DBD-venus plasmid (supplied by
Professor Jia Li), DNA using Lipofectamine 2000 (Invitrogen),
according to the manufacturer’s instructions. Xbp1-DBD-venus
(the gene encoding venus - a variant of the green fluorescent
protein) acts as an indicator of ER stress, as described [44]. Under
ER stress, the transcripts from Xbp1-DBD-venus constructs were
spliced. The spliced mRNA was translated into an Xbp1-venus
fusion protein, which can be detected by its fluorescence.
Immunoprecipitation and mTORC1 kinase assays
Immunoprecipitates were prepared as previously described [45].
For immunoprecipitation experiments, the lysis buffer contained
0.3% CHAPS instead of 1% Triton in order to preserve the
integrity of the mTOR complexes. First, 10 mL of Raptor antibody
was added to the cleared cellular lysates and incubated for 90 min.
25 ml of Protein A/G PLUS-Agarose (Santa Cruz Biotechnology)
was then added and incubated for 1 h. Immunoprecipitates
captured with Protein A/G PLUS-Agarose were washed four times
with the CHAPS Lysis Buffer and once with the mTORC1 kinase
buffer (25 mM Hepes pH 7.5, 100 mM potassium acetate, 1 mM
MgCl2). For kinase reactions, immunoprecipitates were incubated
in a final volume of 40 ml for 20 min at 37uC in the mTORC1
kinase buffer containing 500 ng 4EBP1 fusion protein (Santa Cruz
Biotechnology) and 500 mM ATP. After centrifugation at 6000 rpm
for 1 min, the supernatant was removed from the Protein A/G
PLUS-Agarose and analyzed by immunoblotting [45].
Determination of HIF-1a expression in vivo
Five- to six- week-old BALB/c female athymic mice (weight,
18–22 g) were supplied by the Shanghai Laboratory Animal
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by injection of HepG2 cells (5610
6 cells per animal, subcutane-
ously injected into the armpit of the athymic mice) into mice. Mice
were intraperitoneally administrated TPZ dissolved in physiolog-
ical saline (30 mg/kg) once every two days for 10 days. At the
termination of experiment, animals were sacrificed and tumor
tissues were harvested. From the harvested tissues, lysates were
prepared and frozen tumor sections were prepared on slides. The
lysates were used to evaluate the expression levels of HIF1a by
western blotting and frozen tumor sections were immediately
processed for immunofluorescence analysis.
Measurement of In Vivo Activity
Human hepatic cancer HepG2 xenografts were inoculated in
nude mice as described above. The mice were randomized to
control and treated groups, and received vehicle (physiological
saline) and TPZ (30 mg/kg, i.p. administration) every 2 days for
indicated days. The size of tumors were measured individually
every two days with microcalipers. Tumor volume (V) was
calculated as V = (length6width) 2/2. The individual relative
tumor volume (RTV) was calculated as follows: RTV = Vt/V0,
where Vt is the volume on each day of measurement and V0 is the
volume on the day of initial treatment. Therapeutic effect of
compound was expressed in terms of T/C% and the calculation
formula is T/C (%) = mean RTV of the treated group/mean
RTV of the control group 6100%.
Immunofluorescence
Immunofluorescence was performed as described previously
[46]. Frozen sections (10 mm thick) of HepG2 tumor were
incubated with anti-HIF-1a (1:100) or anti-p-eIF2a (1:50) at 4u
overnight followed by 60 min incubation with a secondary
antibody at room temperature. Nuclei were visualized by staining
DAPI. Fluorescence images were acquired with fluorescence
microscope.
Statistical analysis
Data were presented as means 6 SD, and the significance of the
differences between the values of the groups was determined with
an unpaired Student’s t-test. Differences were considered signif-
icant at P,0.05.
Supporting Information
Figure S1 (A) HeLa cells were exposed to 20 mM TPZ after
being stimulated by epidermal EGF (100 ng/mL) or insulin
(80 U/L) for 4 h at hypoxia. Whole-cell extracts were subjected to
immunoblot analysis. (B) Cells were treated with TPZ under
hypoxic conditions for 4 h and viewed by microscope. Cell
viability was not significantly altered.
Found at: doi:10.1371/journal.pone.0013910.s001 (0.90 MB TIF)
Figure S2 (A) HeLa cells were exposed to varying concentra-
tions of TPZ for 4 h or a single concentration for the indicated
times. HIF-1a mRNA levels were determined by real-time PCR.
The relative fold change of HIF-1a mRNA compared to GAPDH
mRNA in untreated cells under normoxia was arbitrarily set as
1.0. HCT116 cells (B) and A549 cells (C) were exposed to
indicated concentrations of TPZ for 4 h at hypoxia. HIF-1a
mRNA levels were determined by real-time PCR. The relative
fold change of HIF-1a mRNA compared to GAPDH mRNA in
untreated cells was arbitrarily set as 1.0. (D) HeLa cells were
treated with TPZ, together with chloroquine diphosphate (CQ),
under the indicated conditions. The cells were harvested and
lysates were immunoprecipitated with an LC3B antibody. The
conversion of LC3-I to the lower migrating form LC3-II have
been used as a indicator of functional inhibition of the lysosome.
(E) HepG2 cells were pre-incubated with CHX for 3 h in normal
conditions and then placed in fresh medium and treated with or
without 20 mM TPZ for the indicated times under hypoxic
conditions. The cells were harvested and lysates were immuno-
blotted with an HIF-1a antibody.
Found at: doi:10.1371/journal.pone.0013910.s002 (0.91 MB TIF)
Figure S3 TPZ does not affect the Erk and AMPK pathways
and Hsp-family proteins. (A–C) HeLa cells were treated with the
indicated concentrations of TPZ at hypoxia for 4 h. Then, the
cells were collected and detected for western blotting using specific
antibodies.
Found at: doi:10.1371/journal.pone.0013910.s003 (0.43 MB TIF)
Figure S4 Effects of TPZ on HIF-1a target genes. (A–B) HeLa
cells were exposed to varying concentrations of TPZ for 4 h.
PHD3 and VEGF mRNA levels were determined by real-time
PCR. The relative fold changes of PHD3 and VEGF mRNA
compared to GAPDH mRNA in untreated cells under hypoxia
was arbitrarily set as 1.0.
Found at: doi:10.1371/journal.pone.0013910.s004 (0.24 MB TIF)
Figure S5 TPZ does not cause ER stress or activate the
transcription-dependent branch of the UPR. (A–B) RT-PCR
analysis showing induction of UPR targets Grp78 and the
appearance of spliced Xbp1 by Tm, but not by TPZ treatment
of HeLa cells. (C) HeLa cells were transfected with Xbp1-DBD
plasmid and then treated with 20 mM TPZ or 10 mg/mL Tm for
4 h under hypoxic conditions. Fluorescent images were obtained
by fluorescence microscope.
Found at: doi:10.1371/journal.pone.0013910.s005 (2.24 MB TIF)
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